In patients with non-small cell lung cancer (NSCLC), the most frequent oncogene driver mutation in Western countries is Kirsten rat sarcoma viral oncogene homolog (KRAS), andKRAS-mutant NSCLC is associated with smoking. There are various sources of biological heterogeneity ofKRAS-mutant NSCLC, ...
Dong ZY, Zhong WZ, Zhang XC, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res, 2017, 23(12): 3012-3024. doi: ...
手机端浏览获取方式,点击以下链接:(由于部分客户端不让跳转打开,您可以直接选择右上角,以浏览器的方式打开。 KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer PC端浏览获取方式,点击以下链接 KRAS-G12D mutation drives...
Patients with KRAS mutation and treated with a checkpoint inhibitor alone had superior survival compared to patients without the mutation: 21.1 vs 13.6 months. Among patients treated with chemo and immunotherapy, however, there was no significant survival difference between patients with or without the ...
KRAS mutation tumors. Adham et al. validated the KRAS G12 mutation peptide as a bona fide epitope promoting the development of immunotherapy directed against this oncoprotein [91]. Chaft et al. revealed a clinical benefit in a patient with KRAS (G12D) metastatic CRC following the adoptive ...
Tu HY, Chen HJ, Sun YL, Zhou Q, Yang JJ, Yang XN, Lin JX, Yan HH, Zhai HR, Yan LX, Liao RQ, Wu SP, & Wu YL (2017) Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Bl...
validated the KRAS G12 mutation peptide as a bona fide epitope promoting the development of immunotherapy directed against this oncoprotein [91]. Chaft et al. revealed a clinical benefit in a patient with KRAS (G12D) metastatic CRC following the adoptive transfer of KRAS (G12D)-specific T ...
Signal Transduction and Targeted Therapy www.nature.com/sigtrans REVIEW ARTICLE OPEN KRAS mutation: from undruggable to druggable in cancer Lamei Huang1, Zhixing Guo1, Fang Wang1 and Liwu Fu1 ✉ Cancer is the leading cause of death worldwide, and its treatment and outcomes have been ...
Owing to the fact that several immune-checkpoint inhibitors PD-1 or PD-L1 are effective in several cancer types, many clinical studies have become increasingly focusing on designing combinatory approaches with immunotherapy that could achieve synergistic effects. At present, the anti-PD-1 SHR-1210 ...
3.De Langen AJ, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet 2023; 401(10378): 733-746.4. 4.Lixiu Peng, et al. Efficacy of immunotherapy in KRAS-mutant advanced...